Cdc6 contributes to cisplatin-resistance by activation of ATR-Chk1 pathway in bladder cancer cells
Sansan Chen(Southern Medical University), Jinlong Li(Hebei Medical University), Daoyu Yan(Southern Medical University), Shi Li(Wenzhou Medical University), Hongwei Li(Southern Medical University), Zhiming Hu(Changchun University of Science and Technology), Yeping Li(Wenzhou Medical University), Wanlong Tan(Nanfang Hospital), Dianpeng Zheng(Southern Medical University), Yue He(Southern Medical University), Xiang Pang(Nanfang Hospital), Xinglu Chen(Southern Medical University), Xinyang Fu(Nanfang Hospital), Guie Xie(Sun Yat-sen University)
Cited by 79
Related Papers
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Regulation of cisplatin resistance in bladder cancer by epigenetic mechanisms
|Drug Resistance Updates|2023|202
SZ‐685C, a marine anthraquinone, is a potent inducer of apoptosis with anticancer activity by suppression of the Akt/FOXO pathway
|British Journal of Pharmacology|2010|121
GLP-1 treatment protects endothelial cells from oxidative stress-induced autophagy and endothelial dysfunction
|International Journal of Biological Sciences|2018|103